Format

Send to

Choose Destination
Curr Hematol Malig Rep. 2007 Oct;2(4):272-7. doi: 10.1007/s11899-007-0037-8.

Cutaneous T-cell lymphoma: Biologic targets for therapy.

Author information

1
Medical Oncology, Yale Cancer Center,Yale School of Medicine, New Haven, CT 06520, USA.

Abstract

Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

PMID:
20425380
DOI:
10.1007/s11899-007-0037-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center